The Nasdaq delisting is the dominant near-term catalyst — monitor for a return to Nasdaq listing or a reverse stock split plan. The operational improvement is real but the OTC listing severely limits institutional access and liquidity. Watch for Q2 2026 results to validate the guided profitability inflection.
Price Chart
Executive Summary
BIO-key reported Q1 2026 revenue of $2.15M (+34% YoY) and a net loss of $(165K), a significant improvement from $(737K) in Q1 2025. The company guided for Q2 2025 revenue of ~$2.8M (+65% YoY) and expects H1 2026 profitability. However, the stock was recently suspended from Nasdaq and now trades on OTC Markets, a material negative that overshadows the operational improvement.
Key Financial Metrics
Key Facts
- Q1 2026 revenue $2,145,533, up 34% from $1,607,159 in Q1 2025
- Q1 2026 net loss improved to $(165,036) from $(736,545) in Q1 2025
- EPS of $(0.15) vs consensus estimate of $(0.60) — a 75% beat
- Gross margin remained strong at 82%
- Q2 2026 revenue guided to ~$2.8M (+65% YoY); H1 2026 revenue guided to ~$5M (+50% YoY)
- Company expects H1 2026 profitability vs $(1.9M) net loss in H1 2025
- Shares recently suspended from Nasdaq; now trading on OTC Markets under BKYI
- Cash and cash equivalents of $2.24M at quarter end
- Ending shares outstanding of 1.08M post 1-for-10 reverse split
Financial Impact
Revenue growth of 34% YoY to $2.15M; net loss narrowed 78% to $(165K); EPS beat consensus by 75%
Risk Factors
- Nasdaq delisting — shares now trade on OTC Markets with reduced liquidity and institutional access
- Going concern risk — accumulated deficit of $134M and history of losses
- Forward-looking guidance may not materialize; Q1 2026 financial statements not yet reviewed by auditors
- Dependence on large renewals and follow-on orders from a concentrated customer base
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-017518 |
| Document: bkyi20260517_8k.htm | 0001437749-26-017518 |
| Document: 0001437749-26-017518-index-headers.html | 0001437749-26-017518 |
| Document: 0001437749-26-017518-index.html | 0001437749-26-017518 |
| Document: 0001437749-26-017518.txt | 0001437749-26-017518 |
| 8-K Data (Synthetic) | 0001437749-26-017518 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 18d ago | S-1 | $1.65 | awaiting T+60 | — | $2.74 (−66.06%) |
Oct 6, 2026 21d ago | DEFA14A | $1.76 | awaiting T+60 | — | $2.74 (+55.68%) |
Oct 6, 2026 21d ago | 8-K | $1.76 | awaiting T+60 | — | $2.74 (+55.68%) |
Oct 2, 2026 25d ago | 8-K | $1.93 | awaiting T+60 | — | $2.74 (−41.97%) |
Sep 29, 2026 28d ago | Press Release | $3.12 | awaiting T+60 | — | $2.74 (−12.18%) |
Aug 24, 2026 9w ago | DEFA14A | $2.97 | awaiting T+60 | — | $2.74 (+7.74%) |
Aug 14, 2026 10w ago | 8-K | $3.18 | awaiting T+60 | — | $2.74 (+13.84%) |
Aug 13, 2026 10w ago | Press Release | $3.18 | awaiting T+60 | — | $2.74 (−13.84%) |
Aug 10, 2026 11w ago | Press Release | $4.17 | awaiting T+60 | — | $2.74 (−34.29%) |
Jul 28, 2026 13w ago | Press Release | $4.25 $2.10 | ▼ −50.59% | ▼ −54.94% | $2.74 (−35.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers